Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director comp.
CC transcript
Appointed director
MANNKIND CORP (MNKD) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2023 SECOND QUARTER FINANCIAL RESULTS"
05/09/2023 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2023 FIRST QUARTER FINANCIAL RESULTS"
02/23/2023 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m."
11/08/2022 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2022 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 9:00 a.m."
08/09/2022 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2022 SECOND QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m."
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "MANNKIND CORPORATION REPORTS 2021 THIRD QUARTER FINANCIAL RESULTS Conference Call to Begin Today at 5:00 p.m."
02/25/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "3Q 2020 U.S. Afrezza Net Revenue of $7.3 million; +27% vs. 3Q 2019 • 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million; +31% vs. 3Q YTD 2019 • Cash and cash equivalents of $52.4 million at September 30, 2020 • On track to complete Treprostinil Technosphere development activities in 4Q 2020 • Expanded Afrezza commercial and medical teams • YTD Afrezza scientific presentations and publications total 14"
08/05/2020 8-K Quarterly results
05/06/2020 8-K Quarterly results
02/25/2020 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "2Q 2019 Total Revenues of $15.0 million; +285% vs. 2Q 2018 o 2Q 2019 Afrezza Net Revenue was $6.1 million; +62% vs. 2Q 2018 o 2Q 2019 Collaboration and Services Revenue was $8.9 million • Afrezza approved in Brazil • Entered into exclusive marketing and distribution agreement with AMSL for Australia • Completed debt financing, which replaces previous secured debt facility and provides up to $75 million in non-dilutive capital"
05/07/2019 8-K Quarterly results
Docs: "1Q 2019 Total Revenues of $17.4 million o 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 o 1Q 2019 Collaborations and Services Revenue was $12.4 million • 1Q 2019 net loss per share $ vs. $ in 1Q 2018; +68% improvement • Received first $12.5 million milestone payment under United Therapeutics License and Collaboration Agreement • Paid $2.5 million to Deerfield on May 6, 2019 for debt maturity • New scientific data released at ATTD and ACCE and late-breaking abstract accepted for release at ADA in June"
02/26/2019 8-K Quarterly results
11/01/2018 8-K Quarterly results
Docs: "Executed license and collaboration agreement with United Therapeutics for up to $95 million in upfront and milestone payments plus royalties • Executed research agreement for a second Technosphere formulation with United Therapeutics for $10 million • Fifth consecutive quarter with triple digit year-over-year Afrezza Net Revenue growth o 3Q 2018 Afrezza Net Revenue was $4.4 million versus $2.0 million in 3Q 2017; 121% growth. Year-to-date Afrezza Net Revenue was $11.5 million versus $4.7 million; 144% growth. o 3Q 2018 Afrezza Gross Revenue was $8.2 million versus $2.8 million in 3Q 2017; 191% growth. Year-to-date Afrezza 2018 Gross Revenue was $20.1 million versus $7.1 million; 184% growth. o 3Q 2018 Afrezza TRx grew 51% versus 3Q 2017."
08/02/2018 8-K Quarterly results
Docs: "2Q 2018 Afrezza Net Revenue was $3.8 million; 142% growth versus. 2Q 2017 • 2Q 2018 Afrezza TRx grew 71% versus 2Q 2017 • Debt principal reduced by $42.6 million, or 27%, year-to-date • Successfully completed Phase 1 clinical trial of Treprostinil Technosphere • Executed exclusive marketing and distribution agreement with Cipla for Afrezza in India • Presented novel STAT study and AFFINITY-1 hypoglycemia data at ADA 78 th Scientific Sessions"
05/09/2018 8-K Quarterly results
Docs: "Q1 2018 Afrezza Net Revenue was $3.4 million; +184% vs. Q1 2017 • Q1 2018 Net Cash Used in Operating Activities was $21.7 million • STAT study results accepted for presentation at American Diabetes Association’s 78 th scientific sessions • Initiated Phase 1 clinical trial of Treprostinil Technosphere"
02/27/2018 8-K Quarterly results
Docs: "Q4 and 2H 2017 Afrezza net revenue were $4.5 million and $6.4 million vs. 2016, respectively • Q4 and 2H 2017 net cash used in operating activities were $30.0 million and $53.3 million, respectively • Cash and Cash Equivalents were $43.9 million and Restricted Cash was $4.4 million at December 31, 2017 • Recapitalization plan gains momentum: o Raised $57.7 million in a registered direct offering in Q4 o Restructured $27.7 million principal amount of Senior Subordinated Convertible Notes due 2018 to extend the maturity date to October 2021, lower the conversion price to $5.15 and reduce outstanding principal by $4.0 million in exchange for the issuance of common stock o Restructured the Facility Financing Obligation by deferring $10.0 million principal amount due Octobe..."
11/07/2017 8-K Quarterly results
Docs: "MannKind Corporation"
08/07/2017 8-K Quarterly results
Docs: "MannKind Corporation Reports 2017 Second Quarter Financial Results"
05/10/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
11/14/2016 8-K Quarterly results
Docs: "MannKind Corporation Reports 2016 Third Quarter Financial Results - Conference Call to Begin Today at 5:00 PM ET -",
"Excerpt of transcript of conference call held on November 9, 2016"
08/10/2016 8-K Form 8-K - Current report
05/09/2016 8-K Form 8-K - Current report
03/16/2016 8-K Form 8-K - Current report
11/09/2015 8-K Quarterly results
Docs: "MannKind Corporation Reports 2015 Third Quarter Financial Results - Conference Call at 5:00 PM ET on November 9, 2015 -"
08/10/2015 8-K Quarterly results
Docs: "MannKind Corporation Reports 2015 Second Quarter Financial Results - Conference Call at 9:00 AM ET on August 10, 2015 -"
05/07/2015 8-K Quarterly results
Docs: "MannKind Corporation Reports 2015 First Quarter Financial Results - Conference Call at 9:00 AM ET on May 8, 2015 -"
02/24/2015 8-K Quarterly results
Docs: "MannKind Corporation Reports 2014 Fourth Quarter and Full Year Financial Results - Conference Call to Begin Today at 5:00 PM ET -"
11/03/2014 8-K Quarterly results
Docs: "MannKind Corporation Reports 2014 Third Quarter Financial Results - Conference Call to Begin Today at 5:00 PM ET -"
08/11/2014 8-K Quarterly results
Docs: "MannKind Corporation Reports 2014 Second Quarter Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy